[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100354341":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":28,"responsibleParty":46,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":10,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":10,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Nice","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"pediatric population",null,"Pediatric population aged 0 to 15 years with neurofibromatosis type 2",[13],"Other: no intervention",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"no intervention","no intervention in an observational study",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Sophie LEGOUPIL","CONTACT","336 81818020","sophie.legoupil@hotmail.fr",{"name":26,"role":22,"phone":10,"phoneExt":10,"email":27},"Christine CHIAVERINI","chiaverini.c@chu-nice.fr",[29],{"facility":30,"status":31,"city":32,"state":10,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Nice Hospital","RECRUITING","Nice","06000","France","FR",{"type":37,"coordinates":38},"Point",[39,40],7.26608,43.70313,{"lat":40,"lon":39},[43,45],{"name":21,"role":22,"phone":10,"phoneExt":10,"email":44},"legoupil.sophie@hotmail.fr",{"name":26,"role":22,"phone":10,"phoneExt":10,"email":27},{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100354341","cutaneous-and-mucosal-manifestations-of-neurofribromatosis-type-2-in-children-under-15-100354341",false,"NCT03893643","Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15","Multicentre Prospective Observational Study: Resentment of Mucocutaneous Manifestations and the Value of Dermatological Examination in the Early Detection of Type 2 Neurofibromatosis in Children Under 15 Years of Age","Inclusion Criteria:\n\n* age up to 15 years\n* diagnosis of neurofibromatosis type 2\n\nExclusion Criteria:\n\n* refusal to participate in the study\n* informed consent that can not be obtained because of a disability or difficulties with a - language barrier","ALL","0 Years","15 Years",{"count":59,"type":60},1000,"ESTIMATED","OBSERVATIONAL",".Neurofibromatosis type 2 is an inherently autosomal dominant genetic disease, but cases of mosaicism or de novo mutation are not uncommon. the prevalence is estimated at 1 \u002F 60,000. the clinical presentation is based on the appearance of tumors in the central and peripheral nervous system. The current average age of diagnosis is around 25 to 30 years depending on the studies. Currently, the diagnostic criteria are based on the ENT, neurological and opthalmological manifestations of the disease. Cutaneous manifestations have been described in these patients. Except now, mucocutaneous manifestations of the disease are not taken into account for depisatage or diagnosis.\n\nThe purpose of this study would be to identify the different cutaneous and mucosal manifestations in a pediatric population under 15 years of age, and to analyze whether this might be of interest in early detection of the disease in association with other symptoms.",[64,65],"Neurofibromatosis 2","Dermatology\u002FSkin - Other","2026-06-25",{"date":68,"type":69},"2026-06-29","ACTUAL",{"date":71,"type":69},"2019-01-01",{"date":73,"type":60},"2027-06-25",{"name":5,"class":6},1]